(19)
(11) EP 4 815 953 A1

(12)

(43) Date of publication:
07.10.2026 Bulletin 2026/41

(21) Application number: 24827529.9

(22) Date of filing: 27.11.2024
(51) International Patent Classification (IPC): 
A61K 31/519(2006.01)
A61P 17/04(2006.01)
A61P 17/00(2006.01)
A61P 17/10(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/519; A61P 17/00; A61P 17/04; A61P 17/10
(86) International application number:
PCT/US2024/057617
(87) International publication number:
WO 2025/117642 (05.06.2025 Gazette 2025/23)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 01.12.2023 US 202363604937 P
05.01.2024 US 202463617826 P
08.02.2024 US 202463551210 P
07.05.2024 US 202463643875 P

(71) Applicant: Incyte Corporation
Wilmington, DE 19803 (US)

(72) Inventor:
  • CORNWELL, M. Celeste Ferreira
    Wilmington, 19803 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) RUXOLITINIB FOR TREATING HIDRADENITIS SUPPURATIVA (HS)